Accelerating Lung Cancer Management Through Previsit Liquid Biopsy: Results From the LUNG-MAP Study
Pre-visit blood tests for lung cancer speed up molecular diagnosis and treatment decisions by weeks, reducing delays in care.
This LUNG-MAP substudy demonstrates that collecting ctDNA liquid biopsies before the clinic visit substantially reduces the time lag between molecular profiling and treatment decisions for advanced NSCLC. The results support previsit liquid biopsy as a standard workflow improvement in precision oncology programs, with direct implications for faster treatment initiation.
What the study was
- Study design
- Prospective implementation study within LUNG-MAP precision oncology platform
- Population
- Previously treated NSCLC patients enrolled in LUNG-MAP precision oncology biomarker screening
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Clinical lung cancer
Why it surfaced
Prospective LUNG-MAP study demonstrating previsit liquid biopsy reduces treatment delays in NSCLC; directly implementable workflow improvement for precision oncology clinics.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.